Evidence map›Paper›PMID 35592362›Full record

ReviewAustralian prescriber2022

Antidepressants in adolescence.

Phillip Hazell

Open access · diamondAbstract readReview
In one paragraph

Review in Australian prescriber, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Current Phenomenon of Self-Harm in Children and Adolescents.Journal of the Korean Academy of Child and Adolescent Psychiatry · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 2 countries.

University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In adolescence, antidepressants are second-line treatment options after psychological therapy for anxiety and obsessive compulsive disorder. They may be first- or second-line options for severe cases of major depressive disorder. The response to antidepressant treatment is generally good for anxiety and obsessive compulsive disorder, but is less convincing for major depressive disorder. Adolescents who do not respond to an adequate trial of one antidepressant should be referred for a psychiatric opinion. Patients must be monitored for rare but serious adverse effects. These include suicide-related behaviours, switching to mania, and serotonin syndrome.

Indexed as

adolescentantidepressive drugsanxiety disordersdepressive disorderobsessive compulsive disorder

Identifiers

PMID35592362
PMCPMC9081936
OpenAlexW4220756098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.